Sirolimus-eluting stents: A review of experimental and clinical findings

Konstantinos Toutouzas, Carlo Di Mario, Robert Falotico, Takuro Takagi, Goran Stankovic, Remo Albiero, Nicola Corvaja, Antonio Colombo

Research output: Contribution to journalArticle

Abstract

Sirolimus (rapamycin), a macrolide antibiotic with known potent immunosuppressive properties, acts in the first phase (G1) of the cell cycle, blocking its further progression to the phase of DNA synthesis (S). In experimental models, rapamycin is effective in inhibiting smooth muscle cell proliferation and migration after vessel wall injury with balloon angioplasty. These results lead to the clinical application of sirolimus-eluting stents in 45 patients in Sao Paulo and Rotterdam (FIM Registry) and 238 patients in a randomized, European multicenter trial (RAVEL). These trials showed, by angiography and intravascular ultrasound, almost complete abolition of in-stent late hyperplasia up to one year after the procedure. In this review, we describe the experimental and clinical results of sirolimus-eluting stents including our experience of 26 stents implanted in 17 patients. In elective de novo lesions has shown remarkably clear lumens at follow-up angiography and intravascular ultrasound within the stented segments were observed with no lesion progression at the stent margins or thrombosis after a 2 month regimen of aspirin, and ticlopidine or clopidogrel. New large-scale ongoing clinical trials will investigate the efficacy of sirolimus-eluting stentsin lesions that are traditionally associated with high restenosis rates after stent implantation, such as long lesions, bifurcations and instent restenosis.

Original languageEnglish
Pages (from-to)49-57
Number of pages9
JournalZeitschrift fur Kardiologie
Volume91
Issue numberSUPPL. 3
DOIs
Publication statusPublished - 2002

Fingerprint

Sirolimus
Stents
clopidogrel
Angiography
Ticlopidine
Balloon Angioplasty
Macrolides
G1 Phase
Immunosuppressive Agents
Aspirin
Multicenter Studies
Smooth Muscle Myocytes
Cell Movement
Hyperplasia
Registries
Cell Cycle
Thrombosis
Theoretical Models
Cell Proliferation
Clinical Trials

Keywords

  • FIM
  • Rapamycin
  • RAVEL
  • Restenosis
  • Sirolimus
  • Stent

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Toutouzas, K., Di Mario, C., Falotico, R., Takagi, T., Stankovic, G., Albiero, R., ... Colombo, A. (2002). Sirolimus-eluting stents: A review of experimental and clinical findings. Zeitschrift fur Kardiologie, 91(SUPPL. 3), 49-57. https://doi.org/10.1007/s392-002-8371-x

Sirolimus-eluting stents : A review of experimental and clinical findings. / Toutouzas, Konstantinos; Di Mario, Carlo; Falotico, Robert; Takagi, Takuro; Stankovic, Goran; Albiero, Remo; Corvaja, Nicola; Colombo, Antonio.

In: Zeitschrift fur Kardiologie, Vol. 91, No. SUPPL. 3, 2002, p. 49-57.

Research output: Contribution to journalArticle

Toutouzas, K, Di Mario, C, Falotico, R, Takagi, T, Stankovic, G, Albiero, R, Corvaja, N & Colombo, A 2002, 'Sirolimus-eluting stents: A review of experimental and clinical findings', Zeitschrift fur Kardiologie, vol. 91, no. SUPPL. 3, pp. 49-57. https://doi.org/10.1007/s392-002-8371-x
Toutouzas K, Di Mario C, Falotico R, Takagi T, Stankovic G, Albiero R et al. Sirolimus-eluting stents: A review of experimental and clinical findings. Zeitschrift fur Kardiologie. 2002;91(SUPPL. 3):49-57. https://doi.org/10.1007/s392-002-8371-x
Toutouzas, Konstantinos ; Di Mario, Carlo ; Falotico, Robert ; Takagi, Takuro ; Stankovic, Goran ; Albiero, Remo ; Corvaja, Nicola ; Colombo, Antonio. / Sirolimus-eluting stents : A review of experimental and clinical findings. In: Zeitschrift fur Kardiologie. 2002 ; Vol. 91, No. SUPPL. 3. pp. 49-57.
@article{8711f3a0a24e4d8ea985922448ac6eef,
title = "Sirolimus-eluting stents: A review of experimental and clinical findings",
abstract = "Sirolimus (rapamycin), a macrolide antibiotic with known potent immunosuppressive properties, acts in the first phase (G1) of the cell cycle, blocking its further progression to the phase of DNA synthesis (S). In experimental models, rapamycin is effective in inhibiting smooth muscle cell proliferation and migration after vessel wall injury with balloon angioplasty. These results lead to the clinical application of sirolimus-eluting stents in 45 patients in Sao Paulo and Rotterdam (FIM Registry) and 238 patients in a randomized, European multicenter trial (RAVEL). These trials showed, by angiography and intravascular ultrasound, almost complete abolition of in-stent late hyperplasia up to one year after the procedure. In this review, we describe the experimental and clinical results of sirolimus-eluting stents including our experience of 26 stents implanted in 17 patients. In elective de novo lesions has shown remarkably clear lumens at follow-up angiography and intravascular ultrasound within the stented segments were observed with no lesion progression at the stent margins or thrombosis after a 2 month regimen of aspirin, and ticlopidine or clopidogrel. New large-scale ongoing clinical trials will investigate the efficacy of sirolimus-eluting stentsin lesions that are traditionally associated with high restenosis rates after stent implantation, such as long lesions, bifurcations and instent restenosis.",
keywords = "FIM, Rapamycin, RAVEL, Restenosis, Sirolimus, Stent",
author = "Konstantinos Toutouzas and {Di Mario}, Carlo and Robert Falotico and Takuro Takagi and Goran Stankovic and Remo Albiero and Nicola Corvaja and Antonio Colombo",
year = "2002",
doi = "10.1007/s392-002-8371-x",
language = "English",
volume = "91",
pages = "49--57",
journal = "Zeitschrift fur Kardiologie",
issn = "0300-5860",
publisher = "D. Steinkopff-Verlag",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Sirolimus-eluting stents

T2 - A review of experimental and clinical findings

AU - Toutouzas, Konstantinos

AU - Di Mario, Carlo

AU - Falotico, Robert

AU - Takagi, Takuro

AU - Stankovic, Goran

AU - Albiero, Remo

AU - Corvaja, Nicola

AU - Colombo, Antonio

PY - 2002

Y1 - 2002

N2 - Sirolimus (rapamycin), a macrolide antibiotic with known potent immunosuppressive properties, acts in the first phase (G1) of the cell cycle, blocking its further progression to the phase of DNA synthesis (S). In experimental models, rapamycin is effective in inhibiting smooth muscle cell proliferation and migration after vessel wall injury with balloon angioplasty. These results lead to the clinical application of sirolimus-eluting stents in 45 patients in Sao Paulo and Rotterdam (FIM Registry) and 238 patients in a randomized, European multicenter trial (RAVEL). These trials showed, by angiography and intravascular ultrasound, almost complete abolition of in-stent late hyperplasia up to one year after the procedure. In this review, we describe the experimental and clinical results of sirolimus-eluting stents including our experience of 26 stents implanted in 17 patients. In elective de novo lesions has shown remarkably clear lumens at follow-up angiography and intravascular ultrasound within the stented segments were observed with no lesion progression at the stent margins or thrombosis after a 2 month regimen of aspirin, and ticlopidine or clopidogrel. New large-scale ongoing clinical trials will investigate the efficacy of sirolimus-eluting stentsin lesions that are traditionally associated with high restenosis rates after stent implantation, such as long lesions, bifurcations and instent restenosis.

AB - Sirolimus (rapamycin), a macrolide antibiotic with known potent immunosuppressive properties, acts in the first phase (G1) of the cell cycle, blocking its further progression to the phase of DNA synthesis (S). In experimental models, rapamycin is effective in inhibiting smooth muscle cell proliferation and migration after vessel wall injury with balloon angioplasty. These results lead to the clinical application of sirolimus-eluting stents in 45 patients in Sao Paulo and Rotterdam (FIM Registry) and 238 patients in a randomized, European multicenter trial (RAVEL). These trials showed, by angiography and intravascular ultrasound, almost complete abolition of in-stent late hyperplasia up to one year after the procedure. In this review, we describe the experimental and clinical results of sirolimus-eluting stents including our experience of 26 stents implanted in 17 patients. In elective de novo lesions has shown remarkably clear lumens at follow-up angiography and intravascular ultrasound within the stented segments were observed with no lesion progression at the stent margins or thrombosis after a 2 month regimen of aspirin, and ticlopidine or clopidogrel. New large-scale ongoing clinical trials will investigate the efficacy of sirolimus-eluting stentsin lesions that are traditionally associated with high restenosis rates after stent implantation, such as long lesions, bifurcations and instent restenosis.

KW - FIM

KW - Rapamycin

KW - RAVEL

KW - Restenosis

KW - Sirolimus

KW - Stent

UR - http://www.scopus.com/inward/record.url?scp=0036320361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036320361&partnerID=8YFLogxK

U2 - 10.1007/s392-002-8371-x

DO - 10.1007/s392-002-8371-x

M3 - Article

C2 - 12641015

AN - SCOPUS:0036320361

VL - 91

SP - 49

EP - 57

JO - Zeitschrift fur Kardiologie

JF - Zeitschrift fur Kardiologie

SN - 0300-5860

IS - SUPPL. 3

ER -